Joseph A C Delaney1, Stella S Daskalopoulou, Samy Suissa. 1. Department of Biostatistics, Collaborative Health Studies Coordinating Center, University of Washington, Seattle, WA 98115 USA. jacd@u.washington.edu
Abstract
BACKGROUND: Observational studies of the effect of beta-blockers on all-cause mortality after an acute myocardial infarction (AMI) have tended to overestimate the effectiveness of this treatment. OBJECTIVE: To compare the estimates of the effect of beta-blocker use on mortality post-AMI derived from a traditional adjusted regression model with those from a marginal structural model. METHODS: A population-based cohort spanning the period of 2002-2004 was formed from the United Kingdom General Practice Research Database (GPRD). The cohort included all subjects who survived 90 days after their first AMI, who were then followed for 9 months. beta-Blocker use and blood pressure were identified in both the 90-day period before and the 90-day period after the AMI. Rate ratios (RR) were estimated using pooled logistic regression. RESULTS: The cohort included 9939 participants who survived 90 days after their AMI, of whom 633 died during the 9-month follow-up. Over 23% were taking beta-blockers pre-AMI, compared with 71% post-AMI. Using the traditional adjusted regression analysis, the RR of death with post-AMI beta-blocker use was 0.54 (95% confidence interval (CI): 0.45-0.67), while using the inverse probability of treatment weighting (IPTW) model it was 0.72 (95%CI: 0.61-0.84). The IPTW estimate is compatible with the estimate derived from a meta-analysis of randomized controlled trials (RCTs) while the adjusted regression estimate exaggerates the effectiveness. CONCLUSIONS: Observational studies of the association of anti-hypertensive medications with all-cause mortality should consider adding a marginal structural model to their armamentarium of data analysis.
BACKGROUND: Observational studies of the effect of beta-blockers on all-cause mortality after an acute myocardial infarction (AMI) have tended to overestimate the effectiveness of this treatment. OBJECTIVE: To compare the estimates of the effect of beta-blocker use on mortality post-AMI derived from a traditional adjusted regression model with those from a marginal structural model. METHODS: A population-based cohort spanning the period of 2002-2004 was formed from the United Kingdom General Practice Research Database (GPRD). The cohort included all subjects who survived 90 days after their first AMI, who were then followed for 9 months. beta-Blocker use and blood pressure were identified in both the 90-day period before and the 90-day period after the AMI. Rate ratios (RR) were estimated using pooled logistic regression. RESULTS: The cohort included 9939 participants who survived 90 days after their AMI, of whom 633 died during the 9-month follow-up. Over 23% were taking beta-blockers pre-AMI, compared with 71% post-AMI. Using the traditional adjusted regression analysis, the RR of death with post-AMI beta-blocker use was 0.54 (95% confidence interval (CI): 0.45-0.67), while using the inverse probability of treatment weighting (IPTW) model it was 0.72 (95%CI: 0.61-0.84). The IPTW estimate is compatible with the estimate derived from a meta-analysis of randomized controlled trials (RCTs) while the adjusted regression estimate exaggerates the effectiveness. CONCLUSIONS: Observational studies of the association of anti-hypertensive medications with all-cause mortality should consider adding a marginal structural model to their armamentarium of data analysis.
Authors: Michael McCulloch; Michael Broffman; Mark van der Laan; Alan Hubbard; Lawrence Kushi; Donald I Abrams; Jin Gao; John M Colford Journal: Integr Cancer Ther Date: 2011-09-30 Impact factor: 3.279
Authors: Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff Journal: J Comp Eff Res Date: 2015-08 Impact factor: 1.744
Authors: Robert D Gibbons; Marcelo Coca Perraillon; Kwan Hur; Rena M Conti; Robert J Valuck; David A Brent Journal: Pharmacoepidemiol Drug Saf Date: 2014-09-29 Impact factor: 2.890
Authors: Alexander C Tsai; Sheri D Weiser; Maya L Petersen; Kathleen Ragland; Margot B Kushel; David R Bangsberg Journal: Arch Gen Psychiatry Date: 2010-12
Authors: Tobias Gerhard; Joseph Ac Delaney; Rhonda M Cooper-Dehoff; Jonathan Shuster; Babette A Brumback; Julie A Johnson; Carl J Pepine; Almut G Winterstein Journal: BMC Med Res Methodol Date: 2012-08-06 Impact factor: 4.615